FGFR3 dysregulation and clinical outcome in myeloma [1]

British Journal of Haematology

Volumn 120, Issue 1, 2003, Pages 166-

  Rasmussen, Thomas ^a   Hudlebusch, Heidi Rye ^a   Knudsen, Lene Meldgaard ^a   Johnsen, Hans Erik ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

FGFR3; Monoclonal gammopathy of uncertain significance; Multiple myeloma

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3;

CARCINOGENESIS; COHORT ANALYSIS; FOLLOW UP; HUMAN; IMMUNOGLOBULIN GENE; IN SITU HYBRIDIZATION; LETTER; MALIGNANT TRANSFORMATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MUTATIONAL ANALYSIS; ONCOGENE; PRIORITY JOURNAL; RECIPROCAL CHROMOSOME TRANSLOCATION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 4; DISEASE PROGRESSION; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PROTEIN-TYROSINE KINASES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; TRANSLOCATION, GENETIC;

EID: 0037217574     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.03983_1.x     Document Type: Letter

References (7)

1. Avet-Loiseau, H., Facon, T., Grosbois, B., Magrangeas, F., Rapp, M.J., Harousseau, J.L., Minvielle, S. & Bataille, R. (2002) Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood, 99, 2185-2191.
2. Chesi, M., Brents, L.A., Ely, S.A., Bais, C., Robbiani, D.F., Mesri, E.A., Kuehl, W.M. & Bergsagel, P.L. (2001) Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood, 97, 729-736.
3. Fonseca, R., Harrington, D., Blood, E., Oken, M.M., Dewald, G., Kyle, R., Van Wier, S., Henderson, K., Bailey, R. & Greipp, P. (2001a) A molecular classification of multiple myeloma (MM) based on cytogenetic abnormalities detected by interphase FISH, is powerful in indentifying discrete groups of patients with dissimilar prognosis. Blood, 98, 733a.
4. Fonseca, R., Oken, M.M. & Greipp, P. (2001b) The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance. Blood, 98, 1271-1272.
5. Kuehl, W.M. & Bergsagel, P.L. (2002) Multiple myeloma: Evolving genetic events and host interactions. Nature Reviews Cancer, 2, 175-187.
6. Nakazawa, N., Nishida, K., Tamura, A., Kobayashi, M., Iwai, T., Horiike, S., Nishigaki, H., Otsuki, T., Tomiyama, Y., Fujii, H., Kashima, K. & Taniwaki, M. (2000) Interphase detection of t(4;14)(p16.3;q32.3) by in situ hybridization and FGFR3 over-expression in plasma cell malignancies. Cancer Genetics and Cytogenetics, 117, 89-96.
7. Rasmussen, T., Hudlebusch, H.R., Knudsen, L.M. & Johnsen, H.E. (2002) FGFR3 dysregulation in multiple myeloma: Frequency and prognostic relevance. British Journal of Haematology, 117, 626-628.